Midfoot Arthritis Treatment Options: The Injection-Type Selection Framework Based on the 2025 Fluoroscopic Evidence

Introduction: Why Midfoot Arthritis Demands a Smarter Injection Strategy

Symptomatic midfoot osteoarthritis affects approximately 12% of adults over age 50, yet this condition remains underdiagnosed and underappreciated even among orthopaedic specialists. Unlike the knee or hip, no replacement joints are available for the midfoot—fusion stands as the only definitive surgical option, making effective non-surgical management critically important for preserving quality of life.

This article presents a structured, evidence-anchored framework for selecting the right injection type, guidance modality, and patient-profile match. Rather than offering a generic treatment ladder, the framework draws from the landmark 2025 Kulkarni et al. finding: a 94.2% success rate for fluoroscopic-guided corticosteroid injections across 132 patients (155 feet)—a statistic that most competing resources have not yet incorporated into clinical guidance.

The three injection modalities examined include corticosteroid, platelet-rich plasma (PRP), and hyaluronic acid (HA), along with the patient-profile variables that should drive selection. This content is designed to help patients and caregivers engage in more informed conversations with their care teams, not to replace clinical judgment.

Understanding the Midfoot: Anatomy That Shapes Every Injection Decision

The midfoot comprises the tarsometatarsal (TMT/Lisfranc) joints and naviculocuneiform joints—a complex of small, tightly packed articulations that present inherent targeting challenges. The second cuneometatarsal joint is the most commonly affected, found in approximately 50.8% of midfoot OA cases. Its deep anatomical position and proximity to adjacent structures make blind injection unreliable.

Small joint size, overlapping bony architecture, and limited joint space make imaging guidance not merely preferable but clinically essential for accurate therapeutic delivery. Two primary arthritis subtypes influence injection selection: primary osteoarthritis (wear-and-tear) and post-traumatic arthritis following Lisfranc injuries. Inflammatory causes and neuropathic etiologies such as Charcot arthropathy in diabetic patients require separate management considerations.

Weight-bearing CT (WBCT) has demonstrated superiority over conventional X-ray for detecting midfoot arthritis, with 2024 research showing prevalence exceeding 56% in males and 58% in females within studied cohorts—relevant context for pre-injection imaging decisions.

The Conservative Foundation: What Should Come Before Injections

Injections are not a first-line standalone treatment. Conservative care forms the essential foundation, and injections prove most effective when layered alongside these measures.

Core conservative options include:

• Stiff-soled or rocker-bottom shoes
• Custom foot orthotics
• NSAIDs
• Activity modification (switching from running to cycling or swimming)
• Weight loss
• Calf stretching
• Physical therapy

A randomized controlled trial demonstrated improved pain and function with semi-rigid contoured orthoses versus sham inserts over 12 weeks, while full-length inserts reduce medial midfoot loading more effectively than three-quarter-length versions.

When conservative measures provide insufficient relief—typically after three to six months—injection therapy becomes the logical next step before considering surgical referral. Importantly, injections also serve a diagnostic function: a successful response to a corticosteroid injection can confirm the arthritic joint as the primary pain generator and guide surgical planning if fusion is eventually considered.

The Injection-Type Selection Framework: Matching Modality to Patient Profile

Injection selection for midfoot arthritis should not follow a one-size-fits-all approach. The optimal choice depends on disease stage, BMI, prior injection history, cost considerations, and treatment goals.

The framework operates on three tiers:

1. Corticosteroid as the evidence-anchored first-line injection
2. Hyaluronic acid as a complementary or alternative option in early-to-moderate OA
3. PRP as the regenerative escalation when corticosteroids lose efficacy over repeat cycles

Guidance modality represents a parallel decision: fluoroscopic versus ultrasound guidance is not interchangeable for all joints. The choice must account for joint depth, operator expertise, and real-time visualization needs.

Tier 1: Corticosteroid Injections — The Evidence-Anchored Starting Point

Corticosteroids reduce intra-articular inflammation by suppressing cytokine activity and synovial membrane proliferation, providing both pain relief and functional improvement.

The 2025 Kulkarni et al. study established the strongest single-study evidence base for midfoot injection therapy: a 94.2% success rate in 132 patients (155 feet) treated with fluoroscopic-guided corticosteroid injections, averaging 3.1 injections per foot. A separate retrospective audit of 166 patients receiving guided corticosteroid injections showed 51% complete pain relief and 32% partial relief, with mean pain scores dropping from 8.45 to 3.42 and overall satisfaction of 83%.

Current evidence suggests improvement in pain and function for up to three months, though effects may not reliably persist long-term. The 2025 Oxford Academic systematic review concluded that insufficient high-quality RCT evidence exists to guide corticosteroid injection use specifically for foot and ankle OA, and no current clinical guidelines address this anatomical region specifically—a critical nuance for evidence-based practice.

Ideal patient profile for corticosteroids:

• Moderate-to-severe inflammatory flare
• First or second injection cycle
• Good surgical candidates using injections as bridging therapy
• No contraindications to corticosteroids

Fluoroscopic vs. Ultrasound Guidance: Why the Second Cuneometatarsal Joint Changes the Equation

Guidance is non-negotiable for midfoot injections given the small joint size and complex bony anatomy. Fluoroscopy provides real-time X-ray visualization of bony landmarks and contrast spread, confirming intra-articular needle placement with high confidence. Ultrasound offers dynamic soft-tissue visualization without radiation but requires significant operator expertise for deep midfoot joints.

For the second cuneometatarsal joint specifically, its deep anatomical position, narrow joint space, and proximity to the dorsalis pedis artery make fluoroscopic guidance particularly advantageous—the Kulkarni et al. 94.2% success rate was achieved specifically with this approach. Providers offering PRP injection with ultrasound guidance apply comparable imaging precision principles across joint types.

When scheduling a midfoot injection, patients should ask specifically about the guidance modality and the provider’s experience with midfoot anatomy.

How BMI Modifies Corticosteroid Injection Response

Research published in Foot & Ankle International found a statistically significant difference in corticosteroid injection response between obese (BMI ≥30) and non-obese patients, with non-obese patients showing greater improvement in SEFAS scores at both 4 and 12 months.

Excess adipose tissue may alter corticosteroid pharmacokinetics, increase systemic inflammatory burden, and place greater mechanical load on the injected joint. Notably, midfoot arthritis prevalence increases with age and obesity for both genders, meaning the patient population most likely to need injections is also the population most likely to show a blunted response.

For patients with BMI ≥30, providers should set realistic expectations about injection response magnitude and duration while discussing weight management as a parallel intervention.

Tier 2: Hyaluronic Acid Injections — Viscosupplementation for Early-to-Moderate Disease

Hyaluronic acid injections supplement depleted synovial fluid, restoring lubrication and viscoelastic properties within the joint—a mechanism distinct from corticosteroids that targets the structural joint environment rather than acute inflammation.

HA injections are used off-label in midfoot joints, with the evidence base primarily derived from knee OA studies. A 2025 umbrella review found intra-articular hyaluronic acid showed moderate efficacy in pain relief and functional improvement, particularly in early-to-moderate OA, though long-term effectiveness remains unclear and guidelines vary widely.

Emerging combination therapy evidence suggests that combining three corticosteroid injections with hyaluronic acid produced superior pain and function outcomes compared to corticosteroid injections alone for post-traumatic subtalar OA.

Ideal patient profile for HA:

• Early-to-moderate midfoot OA with predominantly mechanical symptoms
• Patients who cannot tolerate or have contraindications to corticosteroids
• Those seeking to extend the interval between corticosteroid cycles

Higher cost relative to corticosteroids and limited insurance coverage for off-label midfoot use represent practical barriers that warrant discussion during patient counseling.

Tier 3: PRP Injections — The Regenerative Escalation When Corticosteroids Lose Efficacy

PRP is derived from the patient’s own blood, concentrated to deliver high levels of growth factors (PDGF, TGF-β, VEGF, IGF-1) that stimulate tissue repair, modulate inflammation, and may slow cartilage degradation—a fundamentally different biological action from corticosteroids.

PRP is not a first-line injection for most patients but becomes the logical escalation when corticosteroids have provided diminishing returns over repeat cycles. Research indicates PRP is associated with decreased need for reinjection or surgery long-term and positive effects on soft tissue regeneration.

Corticosteroids carry risks with frequent repetition, including cartilage degradation and systemic effects. PRP does not carry these same risks, making it a biologically safer option for patients requiring ongoing injection management. Patients considering this transition can review the PRP therapy recovery timeline to understand what to expect following treatment.

Ideal patient profile for PRP:

• Patients who have exhausted two to three corticosteroid injection cycles with diminishing benefit
• Those with early-to-moderate OA seeking regenerative rather than purely palliative treatment
• Active individuals prioritizing long-term joint health
• Patients who are poor surgical candidates requiring sustained non-surgical management

When Injections Are Not Enough: Minimally Invasive and Surgical Pathways

Injections—regardless of type—have a defined therapeutic ceiling. Partial joint denervation offers a minimally invasive procedure that eliminates pain by disrupting nerve signals from arthritic joints without altering joint structure. A pre-procedure lidocaine nerve block test determines candidacy: resolution of 80% of symptoms indicates a good candidate.

Radiofrequency ablation (RFA) uses heat from radio waves to disrupt nerve function and provide long-lasting pain relief without structural joint changes.

Midfoot arthrodesis (fusion) remains the gold standard surgical endpoint, involving removal of articular cartilage and fusing affected joints with screws, plates, or staples. Union rates range from 86.9% to 96%, with good-to-excellent patient satisfaction in 80–90% of cases. A 2025 retrospective cohort study found a mean total cost of $54,307.08 per midfoot arthrodesis—a significant consideration for patients weighing surgical versus non-surgical options. For those exploring alternatives to knee replacement surgery or similar joint-preserving strategies, the same non-surgical principles apply to midfoot management.

Applying the Framework: A Patient-Profile Decision Map

Profile 1 — First-presentation moderate midfoot OA, normal BMI, inflammatory flare: Fluoroscopic-guided corticosteroid injection as first-line; set a three-month efficacy expectation.

Profile 2 — Repeat presentation, BMI ≥30, diminishing corticosteroid response: Consider PRP escalation or a corticosteroid-plus-HA combination; intensify weight management discussion.

Profile 3 — Early-to-moderate OA, mechanical symptoms, corticosteroid contraindicated: Hyaluronic acid as the primary option; discuss off-label status and cost.

Profile 4 — Multiple failed corticosteroid cycles, surgery-averse: PRP as regenerative escalation with realistic expectations.

Profile 5 — End-stage OA, older patient, high surgical risk: Partial joint denervation or RFA as a minimally invasive bridge.

Profile 6 — Diabetic patient with suspected Charcot arthropathy: Requires a distinct management pathway; specialist referral is essential.

Conclusion: The Case for a Precision Approach to Midfoot Arthritis Injection Therapy

Midfoot arthritis treatment is not a simple ladder—injection therapy is a nuanced domain where modality selection, guidance technique, and patient-profile variables meaningfully change outcomes. The 2025 Kulkarni et al. 94.2% success rate for fluoroscopic-guided corticosteroid injections validates the precision-guided approach.

The BMI-guidance-modality-injection-type triad defines a more individualized and effective injection strategy than any generic protocol. As regenerative biologics accumulate more midfoot-specific evidence, this framework will continue to evolve.

Ready to Explore Precision-Guided Injection Therapy for Midfoot Arthritis?

For patients managing midfoot arthritis pain who are considering whether injection therapy—or a different type of injection—might offer better relief, a personalized evaluation represents the essential next step.

Unicorn Bioscience offers the full spectrum of injection modalities discussed in this article: corticosteroid, PRP, hyaluronic acid, and additional regenerative options including BMAC and exosome injection for joint pain. All injections are administered using advanced imaging guidance (ultrasound and X-ray), directly aligned with the fluoroscopic and ultrasound-guided approach the evidence supports for midfoot joints.

Treatment protocols are developed based on individual patient factors including inflammation levels, age, injury type and location, current medications, BMI, and personal health goals. Same-day treatment is available for qualified candidates, with virtual or in-person consultations accessible across multiple locations in Texas, Florida, and New York.

To discuss whether corticosteroid, PRP, hyaluronic acid, or a combination approach fits a specific midfoot arthritis profile, contact Unicorn Bioscience at (737) 347-0446 or visit unicornbioscience.com. Locations include Austin, Dallas, El Paso, Fort Worth, Houston, San Antonio, Boca Raton, and Manhattan.